Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Fogel

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
The World Allergy Organization Journal|October 6, 2021
Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a <i>post-hoc</i> analysis of a randomised phase III studyJing Li, Changzheng Wang, Chuntao Liu, et al.
American Journal of Respiratory and Critical Care Medicine|July 19, 2018
Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAMEStefan M Frent, Kenneth R Chapman, Michael Larbig, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 2, 2018
Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL studyTimm Greulich, Konstantinos Kostikas, Mina Gaga, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 26, 2018
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME studyClaus F Vogelmeier, Kenneth R Chapman, Marc Miravitlles, et al.
American Journal of Respiratory and Critical Care Medicine|May 22, 2018
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical TrialKenneth R Chapman, John R Hurst, Stefan-Marian Frent, et al.
Pragmatic and Observational Research|June 26, 2020
Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort StudyKonstantinos Kostikas, Chin Kook Rhee, John R Hurst, et al.
Asian Pacific Journal of Allergy and Immunology|April 6, 2020
Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and CaucasiansJing Li, Jing Yang, Lingfei Kong, et al.
Respiratory Research|February 11, 2022
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trialDave Singh, Jim M Wild, Dinesh Saralaya, et al.
Dermatologic Therapy|January 5, 2022
Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticariaWeiru Yuan, Shuling Hu, Min Li, et al.
The Lancet. Respiratory Medicine|November 29, 2025
Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trialDavid J Jackson, Njira L Lugogo, Mark Gurnell, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
The World Allergy Organization Journal|October 6, 2021
Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a <i>post-hoc</i> analysis of a randomised phase III studyJing Li, Changzheng Wang, Chuntao Liu, et al.
American Journal of Respiratory and Critical Care Medicine|July 19, 2018
Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAMEStefan M Frent, Kenneth R Chapman, Michael Larbig, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 2, 2018
Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL studyTimm Greulich, Konstantinos Kostikas, Mina Gaga, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 26, 2018
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME studyClaus F Vogelmeier, Kenneth R Chapman, Marc Miravitlles, et al.
American Journal of Respiratory and Critical Care Medicine|May 22, 2018
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical TrialKenneth R Chapman, John R Hurst, Stefan-Marian Frent, et al.
Pragmatic and Observational Research|June 26, 2020
Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort StudyKonstantinos Kostikas, Chin Kook Rhee, John R Hurst, et al.
Asian Pacific Journal of Allergy and Immunology|April 6, 2020
Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and CaucasiansJing Li, Jing Yang, Lingfei Kong, et al.
Respiratory Research|February 11, 2022
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trialDave Singh, Jim M Wild, Dinesh Saralaya, et al.
Dermatologic Therapy|January 5, 2022
Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticariaWeiru Yuan, Shuling Hu, Min Li, et al.
The Lancet. Respiratory Medicine|November 29, 2025
Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trialDavid J Jackson, Njira L Lugogo, Mark Gurnell, et al.
Pageof 4